Bicara Therapeutics Inc. Net Income
Bicara Therapeutics Inc. (BCAX) reported Net Income of -$55.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-11
- Bicara Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$55.44M.
- Bicara Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$56.21M.
- Bicara Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$37.39M.
- Bicara Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$36.33M.
- Bicara Therapeutics Inc. net income (loss) attributable to parent for fiscal 2025 was -$137.95M.
- Bicara Therapeutics Inc. net income (loss) attributable to parent for fiscal 2024 was -$68.00M.
- Bicara Therapeutics Inc. net income (loss) attributable to parent for fiscal 2023 was -$51.98M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$55.44M 10-Q · filed 2026-08-11 | -$111.65M 10-Q · filed 2026-08-11 | -$149.03M derived: sum of 3 quarters · filed 2026-08-11 | -$185.36M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$56.21M 10-Q · filed 2026-08-11 | -$93.60M derived: sum of 2 quarters · filed 2026-08-11 | -$129.93M derived: sum of 3 quarters · filed 2026-08-11 | -$157.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$37.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$73.72M derived: sum of 2 quarters · filed 2026-03-30 | -$101.10M derived: sum of 3 quarters · filed 2026-08-11 | -$137.95M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$36.33M 10-Q · filed 2025-11-10 | -$63.72M derived: sum of 2 quarters · filed 2026-08-11 | -$100.56M 10-Q · filed 2025-11-10 | -$121.52M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$27.39M 10-Q · filed 2026-08-11 | -$64.23M 10-Q · filed 2026-08-11 | -$85.19M derived: sum of 3 quarters · filed 2026-08-11 | -$102.67M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$36.85M 10-Q · filed 2026-08-11 | -$57.80M derived: sum of 2 quarters · filed 2026-08-11 | -$75.28M derived: sum of 3 quarters · filed 2026-08-11 | -$92.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2024-12-31 | -$20.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$38.44M derived: sum of 2 quarters · filed 2026-03-30 | -$55.49M derived: sum of 3 quarters · filed 2026-03-30 | -$68.00M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$17.48M 10-Q · filed 2025-11-10 | -$34.53M derived: sum of 2 quarters · filed 2025-11-10 | -$47.04M 10-Q · filed 2025-11-10 | -$59.48M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$17.05M 10-Q · filed 2025-11-10 | -$29.56M 10-Q · filed 2025-08-12 | -$42.00M derived: sum of 3 quarters · filed 2025-11-10 | -$64.84M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-03-31 | -$12.51M 10-Q · filed 2025-11-10 | -$24.95M derived: sum of 2 quarters · filed 2025-11-10 | -$47.79M derived: sum of 3 quarters · filed 2025-11-10 | -$57.08M derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-12-31 | -$12.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$35.28M derived: sum of 2 quarters · filed 2025-03-27 | -$44.57M derived: sum of 3 quarters · filed 2025-03-27 | -$51.98M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$22.84M 10-Q · filed 2024-11-12 | -$32.13M derived: sum of 2 quarters · filed 2024-11-12 | -$39.55M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$9.29M 10-Q · filed 2024-11-12 | -$16.70M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | -$7.41M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |